Wednesday, 12 Dec 2018

You are here

Can DMARDs Delay Rheumatoid Onset?

Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.

Hilliquin and colleagues undertook a systematic literature review and meta-analysis to assess if there are randomised controlled trials of disease-modifying antirheumatic drugs (DMARDs) or glucocorticoids used in at risk individuals - those with genetic and/or environmental risk factors and/or systemic autoimmunity associated with RA, without clinical synovitis/arthritis. 

They identified 10 trials that included 1156 patients, with mean symptom duration 16.2±12.6 weeks.

In those with  arthralgia, and without arthritis (people at risk of RA), two available studies failed to show significant reduction in RA occurrence at week 52 or more (pooled OR 0.74, 95% CI 0.37 to 1.49).

For people with undifferentiated arthritis, seven studies revealed significant risk reduction with OR 0.73(95% CI 0.56 to 0.97) in the development of RA.

This metanalysis shows that early therapeutic intervention may significantly reduce the risk of RA onset but only those with undifferentiated arthritis.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CV Risks Similar in Systemic Sclerosis and Rheumatoid Arthritis

Interactions between disease-related inflammatory processes and the development of several morbidities have been well-studied in RA, particularly heart disease. This is not the case for the often-lethal SSc (estimated standardized mortality ratio between 2.5 and 4.0). Similarly, there are no studies comparing the most relevant comorbidities between SSc and RA.

PRAIRI Study - Can RA Be Prevented?

B-cell depletion may offer a means of delaying the onset of clinical arthritis in adults at high risk, according to the PRAIRI study - a proof-of-mechanism study in pre-clinical RA patients. 

Rheumatoid Lung Disease Imposes Significant Morbidity and Mortality

Insurance claims data were analyzed for the frequency of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA) and finds that although rare, its frequency increased over time and it is associated with a significant mortality rate. 

The study was done because RA-ILD has been shown to cause significant morbidity and mortality. 

Growing Tick Population Comes with Health Concerns

CNN has published a recent government report from the Tick-Borne Disease Working Group that suggests the US tick population is growing and may bring with it an increase in tick-related illnesses. 

While Lyme disease is the most popular of tick-borne illnesses, there are another 20 known conditions related to tick bites.

Chikungunya Virus Vaccine Developed

Lancet reports on a new vaccine for Chikungunya fever (MV-CHIK) demonstraing excellent safety, tolerability and good immunogenicity, independent of pre-existing immunity against the vector. MV-CHIK is a promising vaccine for the prevention of chikungunya fever.